Early Suspicion of Heparin-Induced Thrombocytopenia for Successful Free Flap Salvage: Reports of Two Cases

Abstract

Heparin-induced thrombocytopenia (HIT) is an underestimated complication of heparin treatment. Flap loss and related morbidity (even mortality) are caused by occlusion of the capillary vessels by a highly immunogenic complex formed by adherence of antiheparin antibodies to platelet factor 4. Early suspicion and effective treatment of HIT developing in two free flaps are described. We report on the management of two patients with HIT. Both patients were treated successfully by early suspicion and hematology consultation. Heparin products were discontinued; the patients were switched to a nonheparin anticoagulant. We emphasize the importance of early diagnosis, hematologist assessment, and a change to a nonheparin anticoagulant to prevent flap failure and possibly the catastrophic consequences of such failure.

Keywords

flap - surgery - fondaparinux - heparin-induced thrombocytopenia

• References

• 1 Tremblay DM, Harris PG, Gagnon AR, Cordoba C, Brutus JP, Nikolis A. Heparin-induced thrombocytopenia syndrome as a cause of flap failure: a report of two cases. J Plast Reconstr Aesthet Surg 2008; 61 (01) 78-83
• 2 Krauel K, Preuße P, Warkentin TE. et al. Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Blood 2019; 133 (09) 978-989
• 3 Harenberg J, Jörg I, Fenyvesi T. Heparin-induced thrombocytopenia: pathophysiology and new treatment options. Pathophysiol Haemost Thromb 2002; 32 (5-6) 289-294
• 4 Samhouri Y, Telfah M, Kouides R, Woodlock T. Utilization of 4T score to determine the pretest probability of heparin-induced thrombocytopenia in a community hospital in upstate New York. J Community Hosp Intern Med Perspect 2016; 6 (04) 32522
• 5 Venkatramani H, Sabapathy SR, Dheenadayalan J, Devendra A, Rajasekaran S. Reconstruction of post-traumatic long segment bone defects of the lower end of the femur by free vascularized fibula combined with allograft (modified Capanna’s technique). Eur J Trauma Emerg Surg 2015; 41 (01) 17-24
• 6 Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108 (09) 2937-2941
• 7 Kowalska MA, Krishnaswamy S, Rauova L. et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood 2011; 118 (10) 2882-2888
• 8 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106 (08) 2710-2715
• 9 Nikolis A, Christopoulos A, Saint-Cyr M, Cordoba C, Guertin L, Harris PG. Recurrent venous thrombosis following free flap surgery: the role of heparin-induced thrombocytopenia. Can J Plast Surg 2003; 11 (01) 37-40
• 10 Joseph J, Rabbolini D, Enjeti AK. et al. Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group. Med J Aust 2019; 210 (11) 509-516
• 11 Bauer KA, Hawkins DW, Peters PC. et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20 (01) 37-52
• 12 Tessler O, Vorstenbosch J, Jones D, Lalonde S, Zadeh T. Heparin-induced thrombocytopenia and thrombosis as an under-diagnosed cause of flap failure in heparin-naive patients: a case report and systematic review of the literature. Microsurgery 2014; 34 (02) 157-163
• 13 Wu W, Merriman K, Nabaah A, Seval N, Afshar-Kharghan V, Yeung SC. Heparin-induced thrombocytopenia among patients of a comprehensive cancer center. SAGE Open Med Case Rep 2014; 2: X145339-45